Table 2.
Univariate Associations With Clinical Outcome.
| Variable | Overall Survival | Recurrence-Free Survival | ||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age, years (≥69 vs <69) | 1.72 (0.83-3.58) | .146 | 1.37 (0.71-2.64) | .352 |
| Sex (female vs male) | 1.15 (0.51-2.57) | .736 | 0.99 (0.47-2.10) | .983 |
| Performance status (≥1 vs 0) | 2.47 (1.20-5.09) | .014 | 2.32 (1.20-4.50) | .013 |
| ACCI score (≥4 vs 0-3) | 1.12 (0.92-1.35) | .232 | 1.09 (0.92-1.28) | .305 |
| Hydronephrosis (present vs absent) | 1.77 (0.81-3.87) | .152 | 1.51 (0.73-3.14) | .269 |
| Carcinoma in situ (present vs absent) | 0.55 (0.21-1.44) | .221 | 0.67 (0.29-1.53) | .343 |
| Multifocality (multiple vs single) | 2.27 (1.04-4.94) | .039 | 2.06 (1.02-4.08) | .045 |
| NLR (≥2.35 vs <2.35) | 2.88 (1.32-6.31) | .008 | 2.59 (1.29-5.19) | .007 |
| CRP, mg/dL (≥0.14 vs <0.14) | 1.58 (0.76-3.28) | .222 | 1.62 (0.83-3.18) | .158 |
| Hemoglobin, g/dL (<12.5 vs ≥12.5) | 2.58 (1.18-5.64) | .017 | 1.86 (0.95-3.63) | .071 |
| Neoadjuvant chemotherapy (yes vs no) | 1.56 (0.76-3.22) | .227 | 1.27 (0.64-2.52) | .488 |
| Pathologic T stage (≥T3 vs ≤T2) | 3.23 (1.13-9.20) | .028 | 2.67 (1.08-6.58) | .033 |
| Pathologic N stage (positive vs negative) | 5.92 (2.70-12.99) | <.001 | 4.88 (2.47-9.66) | <.001 |
| Lymphovascular invasion (positive vs negative) | 5.18 (2.53-10.60) | <.001 | 3.87 (2.02-7.40) | <.001 |
| No. of lymph node removed (≥9 vs <9) | 0.91 (0.45-1.84) | .787 | 1.02 (0.97-1.08) | .466 |
| Adjuvant chemotherapy (yes vs no) | 1.77 (0.85-3.69) | .129 | 1.66 (0.83-3.30) | .153 |
| Squamous differentiation (present vs absent) | 3.14 (1.43-6.91) | .004 | 2.29 (1.07-4.91) | .034 |
Abbreviations: ACCI, age-adjusted Charlson comorbidity index; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; NLR, neutrophil to lymphocyte ratio.